Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated 16 October 2019 (the “Prospectus”) of Ascentage Pharma Group International (the “Company”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute and is not an offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws of the United States and may not be offered or sold in the United States absent registration under the U.S. Securities Act or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offering of securities of the Company in the United States.

ASCENTAGE PHARMA GROUP INTERNATIONAL
亚盛医药
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 6855)

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILISING ACTIONS AND END OF STABILISATION PERIOD

The Company announces that the Over-Allotment Option described in the Prospectus dated 16 October 2019 and the allotment results announcement dated 25 October 2019 (the “Announcement”) has been fully exercised by the Joint Representatives, on behalf of the International Underwriters, on 20 November 2019, in respect of an aggregate of 1,827,100 Shares (the “Over-Allotment Shares”), representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-Allotment Option.

STABILISING ACTIONS AND END OF STABILISATION PERIOD

The Company further announces that the stabilisation period in connection with the Global Offering ended on 20 November 2019, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

Further information of stabilising actions undertaken by the Stabilising Manager during the stabilisation period is set out in this announcement.
FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-Allotment Option described in the Prospectus and the Announcement has been fully exercised by the Joint Representatives, on behalf of the International Underwriters, on 20 November 2019 in respect of 1,827,100 Shares, representing approximately 15% of the Offer Shares initially available under the Global Offering before any exercise of the Over-Allotment Option.

The Over-Allotment Shares will be allotted and issued by the Company at HK$34.20 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Share under the Global Offering.

Approval of Listing

Approval for the listing of and permission to deal in the Over-Allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of and dealings in the Over-Allotment Shares are expected to commence on the Main Board of the Hong Kong Stock Exchange at 9:00 a.m. on 25 November 2019.

Shareholding Structure of the Company upon the Full Exercise of the Over-Allotment Option

The shareholding structure of the Company immediately before and immediately after the completion of the issue of Shares pursuant to the Over-Allotment Option is as follows:

<table>
<thead>
<tr>
<th></th>
<th>Immediately before the allotment and issue of the Over-Allotment Shares</th>
<th>Immediately after the allotment and issue of the Over-Allotment Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of issued Shares</td>
<td>Approximate % of issued share capital</td>
<td>Number of issued Shares</td>
</tr>
<tr>
<td>Founders SPV</td>
<td>53,115,856</td>
<td>25.65%</td>
</tr>
<tr>
<td>Dr. Zhai SPV</td>
<td>14,089,111</td>
<td>6.80%</td>
</tr>
<tr>
<td>Yuanming Entities</td>
<td>20,431,962</td>
<td>9.87%</td>
</tr>
<tr>
<td>Future Industry Investment Co., Limited</td>
<td>19,076,840</td>
<td>9.21%</td>
</tr>
<tr>
<td>Collected Mind</td>
<td>10,140,375</td>
<td>4.90%</td>
</tr>
<tr>
<td>Grand Virtue</td>
<td>10,140,375</td>
<td>4.90%</td>
</tr>
<tr>
<td>RSU Holdco</td>
<td>5,274,657</td>
<td>2.55%</td>
</tr>
<tr>
<td>Other shareholders(1)</td>
<td>62,844,551</td>
<td>30.35%</td>
</tr>
<tr>
<td>Other public shareholders(2)</td>
<td>11,960,900</td>
<td>5.78%</td>
</tr>
<tr>
<td>Total</td>
<td>207,074,627</td>
<td>100.00%</td>
</tr>
</tbody>
</table>

“Other public shareholders” refer to shareholders who subscribe for the Shares of the Company pursuant to the Global Offering.

Use of Proceeds

The Company will receive the net proceeds of approximately HK$58.1 million (after deducting the underwriting commissions and other estimated expenses in connection with the exercise of the Over-Allotment Option) for the 1,827,100 Shares to be issued and allotted following the full exercise of the Over-Allotment Option and will use the net proceeds for the purposes as set out in the section headed “Future Plans and Use of Proceeds” in the Prospectus.

STABILISING ACTIONS AND END OF STABILISATION PERIOD

The Company announces that, pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the stabilisation period in connection with the Global Offering ended on 20 November 2019, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The stabilisation actions undertaken by the Stabilising Manager, its affiliates or any person acting for it during the stabilisation period involved:

1. over-allocations of an aggregate of 1,827,100 Shares in the International Offering, representing 15% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-Allotment Option; and

2. the full exercise of the Over-Allotment Option by the Joint Representatives, on behalf of the International Underwriters, on 20 November 2019, in respect of an aggregate of 1,827,100 Shares, representing 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-Allotment Option, at the Offer Price per Share, to cover the over-allocations in the International Offering.
PUBLIC FLOAT

Immediately after the completion of the issue of Shares pursuant to the Over-Allotment Option, the Company will continue to comply with the public float requirements under Rule 8.08(1) (a) of the Listing Rules.

By order of the Board

Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Hong Kong, 20 November 2019

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Mr. Zhao Qun, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng and Mr. Ren Wei as independent non-executive Directors.